Clinical trial
Thalidomide in Treating Patients With Myelodysplastic Syndrome
NCT00015990 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00015990 |
|---|---|
| Title | Thalidomide in Treating Patients With Myelodysplastic Syndrome |
| Official title | Phase II Study of Thalidomide in the Treatment of Myelodysplastic Syndromes in Adults: A Clinical and Biologic Study |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Ringed Sideroblasts, Secondary Myelodysplastic Syndromes |
| Intervention type | Drug, Other |
| Interventions | thalidomide, laboratory biomarker analysis |
| Enrollment | 29 |
| Start date | Apr 1, 2001 |
| Primary completion | Feb 1, 2007 |
| First posted | Feb 27, 2004 |
| Last update posted | Jan 24, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: